Medicare Enrolled

Dr. Mark Socinski, MD

Hematology & Oncology · Orlando, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
2501 N ORANGE AVE STE 689, Orlando, FL 32804
4073032024
In practice since 2006 (19 years)
NPI: 1740341726 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Socinski from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Socinski? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Socinski

Dr. Mark Socinski is a hematology & oncology in Orlando, FL, with 19 years in practice. Based on federal Medicare data, Dr. Socinski performed 162 Medicare services across 78 unique beneficiaries.

Between the years covered by Open Payments, Dr. Socinski received a total of $2,528,864 from 56 pharmaceutical and/or device companies across 1802 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Socinski is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ 162 Medicare services$ $2,528,864 industry payments

Medicare Practice Summary

Medicare Utilization ↗
162
Medicare services
Bottom 13% in FL for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
78
Unique beneficiaries
$110
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)123$96$381
New patient office visit, complex (60-74 min)21$176$660
Office visit, established patient, complex (40-54 min)18$132$534
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,528,864
Total received (2018-2024)
Avg $361,266/year across 7 years
Top 0% in FL for hematology & oncology
56
Companies
1,802
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,996,245 (78.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$517,476 (20.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,143 (0.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$264,625
2023
$347,699
2022
$420,518
2021
$421,936
2020
$260,966
2019
$416,041
2018
$397,078

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$648,822
Genentech USA, Inc.
$306,151
JAZZ PHARMACEUTICALS INC.
$195,753
Lilly USA, LLC
$187,500
Janssen Biotech, Inc.
$149,523
Regeneron Healthcare Solutions, Inc.
$130,051
G1 Therapeutics, Inc.
$101,646
F. Hoffmann-La Roche AG
$92,522
Celgene Corporation
$72,934
E.R. Squibb & Sons, L.L.C.
$70,251
Eli Lilly and Company
$66,543
Jazz Pharmaceuticals Inc.
$65,397
Takeda Pharmaceuticals U.S.A., Inc.
$60,589
Bayer HealthCare Pharmaceuticals Inc.
$58,345
Merck Sharp & Dohme Corporation
$53,115
Mirati Therapeutics, Inc.
$38,378
Novartis Pharmaceuticals Corporation
$24,891
Blueprint Medicines Corporation
$20,095
GENZYME CORPORATION
$18,235
Amgen Inc.
$16,995
Merck Sharp & Dohme LLC
$14,675
Boehringer Ingelheim Pharmaceuticals, Inc.
$12,991
Janssen Scientific Affairs, LLC
$11,500
Genentech, Inc.
$9,734
EMD Serono, Inc.
$9,380
Gilead Sciences, Inc.
$8,684
AstraZeneca UK Limited
$7,218
NOVARTIS PHARMACEUTICALS CORPORATION
$6,187
AbbVie Inc.
$6,038
Foundation Medicine, Inc.
$5,505
PFIZER INC.
$5,445
Janssen Global Services, LLC
$5,360
SANOFI-AVENTIS U.S. LLC
$5,360
GlaxoSmithKline, LLC.
$5,200
Coherus Biosciences Inc.
$5,054
Daiichi Sankyo Inc.
$4,110
Eisai Inc.
$4,000
Chugai Pharmaceutical Co., Ltd.
$3,960
EISAI INC.
$2,975
TAIHO ONCOLOGY, INC.
$2,935
Novocure Inc.
$2,625
Regeneron Pharmaceuticals, Inc.
$2,534
Heron Therapeutics, Inc.
$2,085
Bayer Healthcare Pharmaceuticals Inc.
$1,750
Exelixis Inc.
$1,320
Mylan Inc.
$1,274
Boehringer Ingelheim International GmbH
$1,198
Acrotech Biopharma LLC
$816
Siemens Medical Solutions USA, Inc.
$604
Pharmacosmos Therapeutics Inc.
$132
BioNTech SE
$118
INTUITIVE SURGICAL, INC.
$88
BeiGene USA, Inc.
$83
TerSera Therapeutics LLC
$75
Spectrum Pharmaceuticals Inc.
$65
Clovis Oncology, Inc.
$50
Top 3 companies account for 45.5% of total payments
Associated products mentioned in payments ›
AFINITOR · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Avastin · BRUKINSA · Bevacizumab · CABOMETYX · COSELA · CYRAMZA · Cabometyx · Da Vinci Surgical System · ENHERTU · EXKIVITY · FOUNDATIONACT · FOUNDATIONONE · GAVRETO · GILOTRIF · Gavreto · IBRANCE · ILARIS · IMFINZI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · Lenvima · MEKINIST · MONOFERRIC · Non-Covered · Non-Covered Product · OFEV · OPDIVO · Optune Lua (NovoTTF-200T) · REBLOZYL · RETACRIT · RETEVMO · ROZLYTREK · RYBREVANT · Rubraca · SUSTOL · TABRECTA · TAGRISSO · TECENTRIQ · TEPMETKO · Tarceva · Tecentriq · Tecentriq Hybreza · Tepmetko · Tepotinib · Trodelvy · Udenyca · VERZENIO · Vitrakvi · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (79%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in FL.

Equivalent to $1,561,027 per 100 Medicare services performed
Looking for a hematology & oncology in Orlando?
Compare hematology & oncologys in the Orlando area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
49
Per 100K population
3.4
County median income
$77,011
Nearest hospital
ASPIRE HEALTH PARTNERS
3.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Socinski is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 0%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Socinski experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Socinski performed 123 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Socinski receive payments from pharmaceutical companies?
Yes. Dr. Socinski received a total of $2,528,864 from 56 companies across 1,802 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Socinski's costs compare to other hematology & oncologys in Orlando?
Dr. Socinski's average Medicare payment per service is $110. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Socinski) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →